EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access

Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments—a systematic review

Alejandro Olivares-Hernández, Elísabet González Del Portillo, Álvaro Tamayo-Velasco, Luis Figuero-Pérez, Svetlana Zhilina-Zhilina, Emilio Fonseca-Sánchez, José Pablo Miramontes-González

Annals of Translational Medicine · 2023-08 · 11 (10) · 354-354

DOI: 10.21037/atm-22-4218 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Annals of Translational Medicine, 2023-08. Verfasst von Alejandro Olivares-Hernández und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, University Hospital of Salamanca, Salamanca, Spain. Die Arbeit wurde bisher 64-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The introduction of immunotherapy in the treatment of non-small cell lung cancer (NSCLC) has resulted in a radical change in patients' treatment responses and survival rates. The increased percentage of long survivors, improved toxicity profiles compared to chemotherapy, and the possible applications for different NSCLC scenarios, have led to immune checkpoint inhibitors (ICIs) becoming the cornerstone of NSCLC treatment. Therefore, the objective of this review is to describe the current and future perspectives of NSCLC treatment.

Methods

A systematic review according to the PRISMA criteria has been performed based on clinical trials with immunotherapy in NSCLC from the start of these treatments until June 2022.

Results

The use of ICIs is widespread across both first- and second-line treatments with anti-PD-1, anti-PD-L1, and anti-CTLA-4 drugs. New indications for immunotherapy in NSCLC have focused on adjuvant (atezolizumab) and neoadjuvant (nivolumab), with ICIs now present in all stages of NSCLC treatment. Given the promising results seen in clinical trials, new ICIs [anti- lymphocyte activation gene-3 (LAG-3) or IDO1] currently under development, will soon be used as standard treatment for NSCLC.

Conclusions

Immunotherapy is the mainstay of NSCLC treatment in all stages, including adjuvant, neoadjuvant and advanced tumors. The development of new molecules will revolutionize the treatment of NSCLC in the coming years.

Schlagwörter

Stichwörter der Autor:innen

anti-CTLA-4anti-PD-1anti-PD-L1immune checkpoint inhibitors (ICIs)non-small cell lung cancer (NSCLC)

Autor:innen und Institutionen

  • Department of Medical Oncology, University Hospital of Salamanca, Salamanca, Spain.
  • Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain.
  • Department of Radiotherapy, University Hospital La Paz, Madrid, Spain.
  • Department of Hematology, University Clínico de Valladolid, Valladolid, Spain.
  • University Hospital Fuenlabrada, Madrid, Spain.
  • Faculty of Medicine, University of Salamanca, Salamanca, Spain.

Zitieren

APA

Olivares-Hernández, A., González Del Portillo, E., Tamayo-Velasco, Á., Figuero-Pérez, L., Zhilina-Zhilina, S., Fonseca-Sánchez, E., & Miramontes-González, J. P. (2023). Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments—a systematic review. Annals of Translational Medicine, 11(10), 354-354. https://doi.org/10.21037/atm-22-4218

Vancouver

Olivares-Hernández A, González Del Portillo E, Tamayo-Velasco Á, Figuero-Pérez L, Zhilina-Zhilina S, Fonseca-Sánchez E, et al. Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments—a systematic review. Annals of Translational Medicine. 2023;11(10):354-354. doi:10.21037/atm-22-4218

BibTeX
@article{OlivaresHernndez2023,
  author = {Olivares-Hernández, Alejandro and González Del Portillo, Elísabet and Tamayo-Velasco, Álvaro and Figuero-Pérez, Luis and Zhilina-Zhilina, Svetlana and Fonseca-Sánchez, Emilio and Miramontes-González, José Pablo},
  title = {Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments—a systematic review},
  journal = {Annals of Translational Medicine},
  year = {2023},
  volume = {11},
  number = {10},
  pages = {354--354},
  doi = {10.21037/atm-22-4218}
}
Kostenlos starten →